Pfizer Jumps 4% as White House to Announce "TrumpRx" Drug-Buying Website, and Deal With Pfizer

Dow Jones
昨天

The White House is planning to unveil a direct-to-consumer website for Americans to buy drugs, dubbed TrumpRx, as well as announce that Pfizer plans to lower prices on several of its medications in the U.S., according to people familiar with the matter.

Shares of Pfizer jumped nearly 4% on the news.

TrumpRx would allow people to pay cash for certain drugs directly from a government website, at a discounted price negotiated by the government. It’s unclear how many drugs would be offered, or whether the website would be useful for the majority of Americans who are already covered by private insurance, Medicare or Medicaid.

Pfizer is expected to be the first to announce a plan to lower drug costs after President Trump pushed companies for months to lower prices in the U.S. More companies are expected to follow suit.

Trump and Albert Bourla, the chief executive of Pfizer, are set to announce the cost-cutting measure at the White House later today, according to a White House official. Bourla is also expected to announce a $70 billion investment on manufacturing medications in the U. S., according to Pfizer spokeswoman Amy Rose and a White House official.

The official estimated Pfizer’s lowered prices could benefit as many as 100 million patients.

「It’s a win for American patients, a win for American leadership, and it’s a win for Pfizer because it provides the certainty and stability we need to continue advancing new breakthrough medicines for patients,」 said Rose. 

「President Trump is leveraging the power of the federal government to drastically cut drug prices for everyday Americans,」 said White House spokesman Kush Desai. 「Democrats talked the talk for decades about drug prices, but only President Trump is actually walking the walk.」

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10